li001

The TCOG T5217 trial compared two intensive chemotherapy regimens for advanced pancreatic cancer: mFOLFIRINOX, a modified global standard, and SLOG, an Asian-specific combination of S-1, leucovorin, oxaliplatin, and gemcitabine. Both treatments provided similar survival benefits, with median overall survival of 12.1 months for mFOLFIRINOX and 12.9 months for SLOG, and comparable progression-free survival and response […]

A new study tested patient-derived organoids (PDOs) from ascites fluid to improve treatment for advanced ovarian cancer. These 3D organoids, created with an 86% success rate, closely replicated the genetics and structure of patients’ tumors, allowing researchers to predict responses to chemotherapy and targeted drugs. Lab results with cisplatin and PARP inhibitors matched patients’ actual one-year

Pancreatic cancer progress is being driven by three main areas: prevention, new treatment technology, and artificial intelligence. Because there is no standard screening for the general public, prevention focuses on quitting smoking, maintaining a healthy weight, and monitoring family history. Doctors also encourage genetic testing for high-risk individuals and are studying the link between high

Results from the Phase 1 DAREON-7 trial, presented at the North American Neuroendocrine Tumor Society (NANETS) 2025 Symposium, showed that adding obrixtamig, a T-cell engager, to standard chemotherapy produced strong responses in patients with DLL3-positive neuroendocrine carcinomas. The study reported a 72% objective response rate, with 88% of patients achieving disease control. The median duration